Tarsa Therapeutics, Inc. has completed its global Phase III ORACAL trial with once-daily oral recombinant calcitonin for the treatment of postmenopausal osteoporosis. The multinational, randomized, double-blind, active and placebo-controlled Phase III trial enrolled 565 postmenopausal women with osteoporosis. Calcitonin, an anti-resorptive agent, has been shown to help maintain bone mass by acting on osteoclasts to limit bone resorption. Tarsa has also initiated a new Phase II study of oral c...